Premium
Making the case for the development of a vaccination against hepatitis E virus
Author(s) -
Haffar Samir,
Bazerbachi Fateh,
Lake John R.
Publication year - 2015
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12590
Subject(s) - hepatitis e virus , vaccination , medicine , fulminant hepatitis , fulminant , hepatitis e , virology , epidemiology , hepatitis a , virus , disease , intensive care medicine , hepatitis , environmental health , immunology , biology , genotype , pathology , biochemistry , gene
Hepatitis E virus ( HEV ) infection is a global problem that affects 20 million individuals, and cause acute hepatitis in 3.5 million, with approximately 70 000 deaths worldwide per year. While the acute disease is generally self‐limited, however, it may progress to fatal fulminant liver failure in certain individuals. Contaminated water supplies disseminate this virus through the faecal–oral route, and swine is thought to be its zoonotic reservoir. Attempts have been made to develop effective HEV vaccines, and two candidates have undergone successful clinical trials. In this review, we discuss HEV epidemiology, genotypes, microbiological structure, as well as the most recent advances in vaccination developments.